Fostemsavir is a novel antiretroviral drug. As an HIV-1 gp120-directed attachment inhibitor, it provides an important treatment option for patients with multiply drug-resistant HIV-1 infection.
Indications for Fostemsavir
Target Patient Population
It is indicated for heavily treatment-experienced adult patients whose current antiretroviral regimens have failed due to drug resistance, intolerance, or safety issues.
Requirements for Combined Medication
It must be used in combination with other antiretroviral drugs and cannot be used alone.
Its mechanism of action is to inhibit the binding of the gp120 protein on the surface of HIV-1 virus to host cells, thereby blocking the virus attachment process.
Dosage Form, Strength, and Properties of Fostemsavir
Dosage Form and Strength
Fostemsavir is supplied as 600 mg extended-release tablets, with each tablet containing the active ingredient fostemsavir tromethamine (equivalent to 725 mg of fostemsavir).
Appearance Characteristics
The tablets are beige, oval-shaped, film-coated tablets with a biconvex design.
One side is engraved with the marking "SV1V7" for easy identification.
Ingredient Description
In addition to the active ingredient, the excipients include colloidal silicon dioxide, hydroxypropyl cellulose, etc. The film coating contains inactive ingredients such as iron oxide red/yellow and polyethylene glycol.
Storage Methods for Fostemsavir
Routine Storage Conditions
It should be stored at room temperature (20°C–25°C); short-term storage in an environment of 15°C–30°C is allowed.
Avoid moisture or direct sunlight, and keep the original packaging to prevent moisture absorption.
Special Precautions
The tablets must be swallowed whole; do not chew, crush, or split them, as this may destroy the extended-release structure.
Keep the medication out of the reach of children to prevent accidental ingestion.
Stability Description
The drug maintains good stability in unopened packaging and does not require refrigeration, but the expiration date should be checked regularly.
Free Inquiry
